TC Biopharm (Holdings) Plc

NasdaqCM:TCBP Stock Report

Market Cap: US$4.3m

TC Biopharm (Holdings) Management

Management criteria checks 3/4

TC Biopharm (Holdings)'s CEO is Bryan Kobel, appointed in Jun 2021, has a tenure of 3.58 years. total yearly compensation is £427.17K, comprised of 83.3% salary and 16.7% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth $1.45K. The average tenure of the management team and the board of directors is 3.3 years and 2.7 years respectively.

Key information

Bryan Kobel

Chief executive officer

UK£427.2k

Total compensation

CEO salary percentage83.3%
CEO tenure3.6yrs
CEO ownership0.03%
Management average tenure3.3yrs
Board average tenure2.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bryan Kobel's remuneration changed compared to TC Biopharm (Holdings)'s earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-UK£12m

Mar 31 2024n/an/a

-UK£9m

Dec 31 2023UK£427kUK£356k

-UK£6m

Sep 30 2023n/an/a

-UK£4m

Jun 30 2023n/an/a

-UK£1m

Mar 31 2023n/an/a

-UK£2m

Dec 31 2022UK£436kUK£363k

-UK£1m

Compensation vs Market: Bryan's total compensation ($USD530.85K) is about average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Bryan's compensation has been consistent with company performance over the past year.

CEO

Bryan Kobel (45 yo)

3.6yrs

Tenure

UK£427,169

Compensation

Mr. Bryan Leland Kobel serves as Chief Executive Officer at TC Biopharm Limited. Mr. Kobel serves as Chief Executive Officer of TC Biopharm (Holdings) Plc since June 2021 and serves as Director. He joined...

Leadership Team

NamePositionTenureCompensationOwnership
Bryan Kobel
CEO & Director3.6yrsUK£427.17k0.029%
$ 1.2k
Martin Thorp
CFO & Director5.8yrsUK£322.02k0.000010%
$ 0.4
Christopher Camarra
Executive Vice President of Communications3yrsno datano data
Lauren Bor
Head of Commercial Development Division1.1yrsno datano data

3.3yrs

Average Tenure

Experienced Management: TCBP's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Bryan Kobel
CEO & Directorno dataUK£427.17k0.029%
$ 1.2k
Martin Thorp
CFO & Director8.8yrsUK£322.02k0.000010%
$ 0.4
Arlene Morris
Non-Executive Independent Chair2.9yrsUK£23.53k0%
$ 0
Mark Bonyhadi
Chairman of Scientific Advisory Board2.7yrsUK£23.53k0%
$ 0
A. Culverwell
Non-Executive Independent Director2.9yrsUK£23.53k0%
$ 0
Isabelle Riviere
Member of Scientific Advisory Board2.3yrsno datano data
Daniel Olive
Member of Scientific Advisory Board2.3yrsno datano data
Uma Lakshmipathy
Member of Scientific Advisory Board2.7yrsno datano data
Erin Adams
Member of Scientific Advisory Board2.7yrsno datano data
Blythe Sather
Member of Scientific Advisory Board2.3yrsno datano data
Chris Bond
Member of Scientific Advisory Board2.3yrsno datano data

2.7yrs

Average Tenure

70yo

Average Age

Experienced Board: TCBP's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 01:44
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TC Biopharm (Holdings) Plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mitchell KapoorH.C. Wainwright & Co.